and biotech companies from around the world are aggressively competing to
bring to market new ways to introduce a variety of drugs through the dermis
without the traditional skin-breaking techniques associated with the
"traditional" needle, reports Strategic Research Institute.
Needleless injection, "pen" injection, transcutaneous "blasting" and
other commercial technologies have come a long way in delivering medicines and
are the current rage at the Ninth International Drug Delivery Technologies &
Deal-Making Summit taking place Sept. 27-29 in Cherry Hill, NJ.
The ninth annual meeting will present many new companies on the leading
edge of transdermal and transcutaneous delivery systems unveiling new
products in an ample range of therapeutic indications. These include Altea,
Shire, Eurand, 3M, Antares, Bioject, Eli Lilly, Aventis, Becton-Dickinson,
Aradigm, Felton, Nobex, and BioValve Technologies.
In addition to the needleless transdermal section of the agenda, the
newly expanded agenda features nearly 75 expert speakers on a variety of
commercial delivery applications, many of which are in clinic or beyond. The
three-day annual information and networking extravaganza has generated a
worldwide buzz. The meeting is geared around commercial talks from the
pharma, biotech, and drug delivery companies in search of partners and the
financial community in search of investments.
The industry is actively interested in many routes of insulin delivery and
delivery vehicles for other disease states as well as diabetes. Partnering
opportunities abound in inflammation, asthma, cancer delivery, anti-infective,
dermotologic, and cardiovascular indications. In addition to the conference
sessions, networking functions studded throughout the 2004 gathering foster
new relationships among the pharmaceutical and delivery companies.
Source: Strategic Research Institute